Merck & Co., Inc. (MRK) Phase 3 ADC Cuts Risk of Death 32% in Endometrial Cancer

What happened

Merck reported Phase 3 TroFuse-005 data showing sacituzumab tirumotecan cut the risk of death by 32% versus chemotherapy in previously treated endometrial cancer. The FDA accepted a priority review, with a PDUFA target date of June 15, 2027.

Confirmed

Global impact / market context

This is a late-stage trial result tying a Merck cancer drug to longer survival, which could support approval and future revenue. A defined FDA review path also gives investors a clearer timeline for a possible U.S. launch.

Analyst inference

Merck's oncology pipeline now has a first Phase 3 win for this drug class, widening its cancer footprint. Its value to investors depends on FDA label scope, pricing, safety adoption, and results from other ongoing Phase 3 trials.

Analyst inference

What to watch

1. The FDA priority review has a PDUFA target of June 15, 2027, which is the agency's target date for deciding on approval; this sets a potential U.S. launch timing signal. Confirmed
2. Detailed FDA review progress, final label scope, and pricing decisions are proposed next catalysts that could shape how widely the drug is used and how much revenue it generates. Proposed
3. A higher share of patients had severe treatment-related side effects than with chemotherapy; higher severe side effects could affect label wording and how quickly doctors adopt the drug. Analyst inference

Evidence

• Original source link unavailable